The staphylococcal QacR multidrug regulator binds a correctly spaced operator as a pair of dimers by Grkovic, Steve et al.
  
10.1128/JB.183.24.7102-7109.2001. 
2001, 183(24):7102. DOI:J. Bacteriol. 
Richard G. Brennan and Ronald A. Skurray
Steve Grkovic, Melissa H. Brown, Maria A. Schumacher,
 
Operator as a Pair of Dimers
Regulator Binds a Correctly Spaced 
The Staphylococcal QacR Multidrug
http://jb.asm.org/content/183/24/7102
Updated information and services can be found at: 
These include:
REFERENCES
http://jb.asm.org/content/183/24/7102#ref-list-1at: 
This article cites 37 articles, 17 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://jb.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 M
ay 3, 2012 by FLINDERS UNIVERSITY O
F SO
UTH AUSTRALIA
http://jb.asm.org/
D
ow
nloaded from
 
JOURNAL OF BACTERIOLOGY,
0021-9193/01/$04.000 DOI: 10.1128/JB.183.24.7102–7109.2001
Dec. 2001, p. 7102–7109 Vol. 183, No. 24
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
The Staphylococcal QacR Multidrug Regulator Binds a
Correctly Spaced Operator as a Pair of Dimers
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Expression of the Staphylococcus aureus plasmid-encoded QacA multidrug transporter is regulated by the
divergently encoded QacR repressor protein. To circumvent the formation of disulfide-bonded degradation
products, site-directed mutagenesis to replace the two cysteine residues in wild-type QacR was undertaken.
Analysis of a resultant cysteineless QacR derivative indicated that it retained full DNA-binding activities in
vivo and in vitro and continued to be fully proficient for the mediation of induction of qacA expression in
response to a range of structurally dissimilar multidrug transporter substrates. The cysteineless QacR protein
was used in cross-linking and dynamic light-scattering experiments to show that its native form was a dimer,
whereas gel filtration indicated that four QacR molecules bound per DNA operator site. The addition of
inducing compounds led to the dissociation of the four operator-bound QacR molecules from the DNA as
dimers. Binding of QacR dimers to DNA was found to be dependent on the correct spacing of the operator
half-sites. A revised model proposed for the regulation of qacA expression by QacR features the unusual
characteristic of one dimer of the regulatory protein binding to each operator half-site by a process that does
not appear to require the prior self-assembly of QacR into tetramers.
Multidrug efflux transporters are membrane proteins found
in both prokaryotes and eukaryotes that confer resistance to a
wide range of structurally unrelated cytotoxic compounds, typ-
ically hydrophobic cations. The mechanisms used by these
transporters to bind and export such a broad range of sub-
strates remain unknown, largely due to the difficulties posed by
the structural analysis of integral membrane proteins. In the
case of bacteria, a fruitful alternative approach has been the
study of cytosolic multidrug-binding proteins that regulate the
expression of specific multidrug transporters at the local level.
Examples of both activators (1, 2) and repressors (7, 16, 17) of
transcription have been described and can be typically found
encoded adjacent to the gene encoding the membrane pump.
Structural analysis of BmrR, a dimeric Bacillus subtilis tran-
scriptional activator that binds a range of ligands similar to its
cognate transporter, Bmr (18, 19, 35), revealed a crucial neg-
atively charged residue buried at the base of an internal drug-
binding pocket lined with hydrophobic residues (38, 39).
Although such an arrangement represents an ideal solution
to the problem of binding structurally diverse, hydrophobic,
cationic ligands, it remains to be seen if different regulatory
proteins, and the efflux pumps themselves, employ a similar,
functionally analogous mode of multidrug binding. However, it
is somewhat surprising that the multidrug-binding domains of
these bacterial regulatory proteins show no apparent homology
even though many of them bind a number of common ligands.
Thus, further analysis of distinct multidrug-binding proteins is
required in order to dissect whether they employ any common
themes in their interactions with ligands or instead possess
discrete substrate-binding mechanisms.
For the important human pathogen Staphylococcus aureus, a
number of plasmid-encoded multidrug resistance transporters
have been described, including the closely related major facil-
itator superfamily members QacA and QacB and the small
multidrug resistance protein Smr (15, 22). Expression of both
qacA and qacB is regulated by a divergently encoded transcrip-
tional repressor, QacR, a member of the TetR family of re-
pressors (25). IR1, a large inverted repeat located immediately
adjacent to and downstream from the qacA and qacB promot-
ers, has been shown to be the site of QacR binding (7). IR1 is
unusually large for an operator sequence bound by a TetR
family regulator, comprising 15-bp half-sites separated by a
6-bp spacer region (7). In contrast, the DNA-bound structure
of TetR indicated that a dimer of TetR, or a similar protein
such as QacR, would be unlikely to span a 6-bp spacer (20).
Furthermore, TetR binding is prevented by a 1-bp increase or
decrease in the single-base-pair spacing between the two tet
operator half-sites (37).
Addition of structurally diverse QacA substrates from a wide
range of chemical classes, including the compounds benzalko-
nium, dequalinium, ethidium, proflavine, and rhodamine 6G,
has been demonstrated to result in both derepression of the
qacA promoter in vivo and dissociation of QacR from qacA
promoter-operator DNA in vitro (7). In order to accommodate
this range of ligands, it has been proposed that a QacR binding
pocket would have to differ substantially from that of the
BmrR multidrug-binding protein (13). However, further bio-
chemical and structural investigations of the DNA- and ligand-
binding properties of QacR have been seriously hampered by
rapid postpurification formation of nonnative disulfide-bonded
monomers and oligomeric aggregates (7).
In this paper, the significance of the two cysteine residues
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within QacR, C72 and C141, to DNA and ligand binding is
examined, with a view to generating a fully functional cysteine-
less QacR derivative for further in vitro studies. Analysis of a
cysteineless QacR derivative resulted in the demonstration of
an intriguing oligomerization state for DNA-bound QacR,
which was found to be dependent on correctly spaced operator
half-sites.
MATERIALS AND METHODS
Bacterial strains and plasmids. Escherichia coli strain DH5 (26), used as the
host for all the procedures described throughout this work, was cultured at 37°C
in Luria-Bertani (LB) medium containing ampicillin (100 g ml1) to select for
plasmids. The plasmid pSK5203, containing the qacA promoter (PqacA) fused to
a chloramphenicol acetyltransferase (cat) reporter gene, and the related plasmid
pSK5212, in which qacR is present in cis to the PqacA-cat fusion, have been
described previously (7), as has pSK5210, a clone of wild-type qacR in the
expression vector pTTQ18 (32). Site-directed mutagenesis reactions were done
with either single-stranded template DNA and a single primer (10) or the
QuickChange kit (Stratagene), employing a pair of complementary oligonucle-
otides and a double-stranded DNA template.
Three restriction endonuclease cleavage sites that do not occur in most com-
monly used plasmid vectors were inserted into a qacR-encoding DNA fragment
by site-directed mutagenesis to facilitate future manipulations. A BglII site was
first inserted into pSK5212 between the promoter and ribosome-binding site of
qacR, at position 692 of the originally described qacA-qacR sequence (25), to
create pSK5213. This plasmid was used as the template for further site-directed
mutagenesis, inserting an MluI site at position 293 and a BsrGI site at position
425 to generate pSK5618. Both these changes were within the coding region of
qacR but did not result in the alteration of any QacR amino acids.
Mutagenesis of the cysteine residue at position 72 (C72) in QacR was per-
formed by replacing the BglII-BsrGI fragment of pSK5618 with a fragment
generated by PCR, using the primer 5-CATTGTACAAATAAAATTTTTCTC
TATTAGTTTTAGNTTTGATTTGTTCC-3, where N is A, C, G, or T and the
BsrGI site is in italics, with the second primer being the same as that used
originally to insert the BglII site. pSK5618 was also used as the template for the
site-directed mutagenesis of the C141 residue of QacR, using the primer pair
5-TTAAATGGCGAATGGNCTATTATGACGTCAATGCTGTTAGTAAA-3
and 5-TTTACTAACAGCATTGACGTCATTAATAATAGNCCATTCGCCA
TTTAA-3, with the AatII site introduced by these primers in italics. Plasmids
encoding cysteineless QacR derivatives were produced by employing the unique
PstI-MluI sites in these plasmids (Fig. 1) to replace the PstI-MluI fragment of the
C72A single mutant with the corresponding fragments from the C141S- and
C141A-encoding plasmids, generating pSK5637 (Fig. 1) and pSK5638, respec-
tively. For overexpression of the C72A/C141S double mutant, the cysteineless
QacR-encoding fragment from pSK5637 was recloned in the expression vector
pTTQ18, as described previously for wild-type QacR (7), yielding the construct
pSK5676.
For mutagenesis of nucleotides within IR1, plasmid pSK5249 was constructed,
which was essentially identical to pSK5213 except for the possession of a KpnI
site located between the IR1 sequence and HindIII site. Mutations were then
produced in the 6-bp spacer region separating the two IR1 half-sites by using
PCR-generated fragments amplified from pSK5249 to replace the PstI-KpnI
fragment of this plasmid. The primers used to achieve this were 5-GAATTCC
CGGGGATCCGTCGACCTG-3 and 5-TTGGGTACCAATCCTTATAGAC
CGXCGGTCTATAAGGATTATAATC-3, where X is ATCA (pSK5834),
ATCAGGCA (pSK5856), GCGATT (pSK5857), ATGCCA (pSK5858), or
TACGCA (pSK5859). An initial mutant, pSK5688, in which the qacA promoter
had been repositioned so that its 10 region, TATAAT, entirely replaced the
6-bp spacer region, was also constructed by PCR in a similar fashion.
CAT assays. Chloramphenicol acetyltransferase (CAT) assays to ascertain the
level of transcription from PqacA were performed as described previously (7),
except that the level of CAT activity was adjusted for the protein concentration
in the cell lysates, determined using the Coomassie protein assay reagent kit
(Pierce).
Protein purification and stability. Overexpression and purification of wild-
type (encoded by pSK5210) and the C72A/C141S cysteineless QacR derivative
(encoded by pSK5676) were carried out with a C-terminal His tag as described
previously (7), with the following minor modifications. All the buffers were pH
7.5 and contained 20 mM 2-mercaptoethanol and 20 mM Tris-HCl or, in the case
of the sonication buffer, 40 mM Tris-HCl. Exchange of proteins into alternative
buffers was achieved by passage through Sephadex G50 (Amersham Pharmacia
Biotech) columns previously equilibrated with the new buffer.
The in vitro stability of QacR was assessed by incubation of the indicated
amounts of purified protein in 20 mM Tris-HCl (pH 7.5) in a final volume of 40
l for 4 h at 22°C. This was followed by the addition of 0.5 volume of sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer
containing 30 mM EDTA, and for selected reactions dithiothreitol (DTT) was
added to a final concentration of 33 mM, before heating of the samples at 100°C
for 4 min and separation by SDS–15% PAGE (11), followed by silver staining.
Gel mobility shift assays were performed as described previously (7). As an
indicator of the in vivo stability of QacR mutants, whole-cell lysates prepared
from overnight cultures harboring QacR-encoding plasmids were separated by
SDS–15% PAGE before being transferred to a Hybond-C nitrocellulose mem-
brane (Amersham Pharmacia Biotech). QacR was then detected immunologi-
cally with an anti-His (C terminus) immunoglobulin G monoclonal antibody
(Invitrogen) at a dilution of 1:250, but otherwise as described in the protocol
supplied by the manufacturer.
Gel filtration. A fast protein liquid chromatography Superose 12 HR 10/30
column (Amersham Pharmacia Biotech) with a mobile phase of 300 mM NaCl,
5% (vol/vol) glycerol, and 20 mM Tris-HCl, pH 7.5, was used in all gel filtration
experiments. Blue dextran (Sigma) was used to determine the column void
volume, and proteins for use as gel filtration molecular mass standards were
purchased from Sigma (carbonic anhydrase and -amylase) and Bio-Rad (myo-
globin, ovalbumin, and gamma globulin). The molecular weights of the experi-
mental samples were determined following the protocols supplied by the man-
ufacturers. Gel filtration was also used to separate QacR from high-molecular-
mass nonspecific protein aggregates before the resultant fractions were stored in
dilute single-use aliquots at 70°C at a concentration of approximately 10 g
ml1 for use in cross-linking reactions. Subsequent chromatography failed to
detect the formation of any further aggregates following storage of these low-
concentration samples.
Protein cross-linking. Cross-linking reactions were performed in 1 cross-
linking buffer (100 mM KCl, 15 mM Tris-HCl, pH 7.5) in a total volume of 40 l,
containing the specified amounts of C72A/C141S QacR and, where indicated,
annealed 28-bp gel-purified IR1 oligonucleotide duplexes (Fig. 1). Reactions
were incubated at 22°C for 15 min before the addition of gluteraldehyde to a final
FIG. 1. The cysteineless QacR derivative encoded by pSK5637 and
relevant details of the cloned HindIII fragment in this plasmid. The
QacR polypeptide encoded by pSK5637 is represented as a rectangular
box showing the positions of the amino-terminal (N) HTH DNA-
binding motif, the carboxy-terminal (C) hexahistidine tag (Histag), and
the two mutations at cysteine residues 72 and 141 that have been
introduced into this QacR derivative. Below this is a linear map of the
cloned qacR-encoding fragment in plasmid pSK5637, depicting the
locations of the qacR and qacA ribosome-binding sites (RBS), the qacR
promoter, PqacR, and the divergent qacA promoter, PqacA, which in this
construct is fused to a cat reporter gene. Also shown are the AatII,
MluI, BsrGI, and BglII restriction endonuclease sites introduced dur-
ing the course of this work and the position of the QacR binding site,
IR1. The sequence of the PqacA 10 hexamer (overlined) is given,
downstream from which the highlighted IR1 bases represent nucleo-
tides protected in DNase I footprinting experiments (7). The sequence
of the 28-bp IR1 annealed oligonucleotide duplex used throughout this
work corresponds to positions 14 to 14 of the IR1 sequence. The
nucleotide numbering is the same as for the originally published qacA-
qacR sequence (25).
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concentration of 0.01%, followed by a 1.5-min incubation to cross-link any QacR
complexes. Alternatively, formaldehyde was used as the cross-linking agent at a
final concentration of 1%, with a 10-min incubation at 22°C. Cross-linking reac-
tions were stopped by the addition of 20 l of 2 SDS gel loading buffer, and the
samples were heated at 95°C for 3 min before separation by SDS–12.5% PAGE
and transfer to a Hybond-C membrane. QacR was detected immunologically
using a 1:1,500 dilution of a rabbit polyclonal antibody raised against the purified
C72A/C141S QacR derivative at the Institute of Medical and Veterinary Science,
South Australia. The resultant serum was used in standard Western blotting
procedures with Blotto as the blocking agent (26).
DLS. The concentration of apo-QacR used in dynamic light-scattering (DLS)
experiments was 10 M (monomer concentration) in a solution of 300 mM NaCl,
1 M imidazole, 5% glycerol, and 50 mM Tris, pH 7.5. When either the 28-bp IR1
or a 33-bp noncognate site was included, the QacR and DNA concentrations
were both 40 M (monomer concentration), and the measurements were con-
ducted in solutions of 50 mM NaCl and 20 mM Tris, pH 7.5. Each experiment
used 100-l samples, which were microfiltered using a 0.02-m-diameter filter.
DLS was measured using a DynaPro 801 dynamic light scattering instrument
(Protein Solutions). Data were adjusted for glycerol content and analyzed using
the instrument control software package Dynamics 4.0 provided by the manu-
facturer. Up to 40 readings were recorded during each DLS experiment. Read-
ings in which the baseline error of the data was less than 1.005 and the sum of
squares error was below 5.000 (indicative of a monodisperse solution) were fit
with a monomodal analysis; all other data were fit using a bimodal analysis.
RESULTS
Site-directed mutagenesis of QacR cysteine residues. The
formation of disulfide bonds during the purification and stor-
age of proteins results from the oxidation of free thiol groups,
a process catalyzed by divalent metal cations (36), as has been
demonstrated for QacR (7). Relatively high levels of reducing
agents and the addition of EDTA only served to partially slow
the formation of the disulfide-bonded forms of QacR (7).
Therefore, site-directed mutagenesis was used to alter the
QacR cysteine codons, producing eight QacR single-amino-
acid substitution mutants, with C72 and C141 changed sepa-
rately to alanine (A), serine (S), threonine (T), or proline (P).
The in vivo stability of the mutant QacR proteins was then
assessed by Western analysis using a C-terminal His tag-spe-
cific monoclonal antibody. Not surprisingly, both the radical
replacements of cysteine with proline resulted in highly unsta-
ble proteins; no band corresponding to the 23-kDa QacR pro-
tein could be detected immunologically (Fig. 2). An unantici-
pated observation was the very unstable nature in vivo of
mutants in which the C72 residue was replaced with either
serine or threonine (Fig. 2), both representing changes that are
normally considered relatively conservative substitutions. All
eight QacR derivatives were also analyzed for their in vivo
DNA-binding abilities. The degree to which each mutant con-
tinued to suppress transcription from PqacA closely correlated
to its intracellular stability (Fig. 2). The nearly wild-type levels
of repression observed for the QacR C72A and C141S deriv-
atives clearly indicated that neither of the two cysteine residues
plays a significant role in functions related to DNA binding.
Cysteineless QacR derivative is fully functional. CAT assays
were used to determine the in vivo inducibility of the most
promising cysteine substitutions in response to the presence of
a monovalent or bivalent inducing compound, ethidium or
dequalinium, respectively. Following the addition of these
compounds, wild-type levels of induction from PqacA were ob-
served in the presence of the divergently encoded C72A,
C141A, or C141S mutant QacR proteins (data not shown).
These results indicated that the cysteine residues in QacR
could be individually replaced by these alternative amino acids
without adversely affecting the ability of the protein to bind
structurally diverse ligands. Therefore, two cysteineless QacR
mutants, with C72 changed to alanine and C141 changed to
alanine (pSK5638) or serine (pSK5637), were produced. For
the C72A/C141S double mutant, both the in vivo protein sta-
bility (Fig. 2) and the amount of transcription it permitted
from PqacA, as determined by CAT assays (0.93-fold the activity
found for wild-type QacR; Fig. 2), were essentially indistin-
guishable from that of QacR containing two cysteine residues.
However, even though the QacR C72A/C141A double mutant
was slightly less stable in vivo, it exhibited enhanced repression
of PqacA (0.85-fold) (Fig. 2).
Both of the QacR cysteineless mutants continued to be com-
pletely proficient for the induction of expression from PqacA in
response to the presence of a wide range of monovalent and
bivalent inducing compounds from a number of chemical
classes (Table 1). Thus, since the C72A/C141S derivative ex-
hibited wild-type properties for all the attributes tested, it was
chosen as the fully functional cysteineless QacR variant to be
the subject of further analysis. Subsequent to its recloning in
the expression vector pTTQ18, the QacR C72A/C141S deriv-
ative was overexpressed and purified in tandem with wild-type
QacR protein. Gel mobility shift assays demonstrated that the
purified cysteineless QacR protein bound to IR1-containing
DNA in vitro with equal or greater affinity than the wild-type
protein (data not shown). Purified C72A/C141S QacR was also
used to raise a rabbit polyclonal antibody, which proved to
have significantly improved sensitivity for the immunological
detection of QacR in Western blot analysis in comparison to
commercially available His tag-specific monoclonal antibodies
(data not shown).
FIG. 2. In vivo stability and DNA-binding abilities of QacR vari-
ants. The cysteine residues (C141 and C72) in wild-type (WT) QacR
were individually replaced with proline (P), serine (S), alanine (A), or
threonine (T), in addition to the production of two cysteineless QacR
derivatives, C72A/C141S and C72A/C141A. Equal amounts of whole-
cell lysates, as judged by Coomassie staining, were separated by SDS–
15% PAGE before being transferred to nitrocellulose, and a Western
blot was performed with a C-terminal His tag-specific primary anti-
body to determine the in vivo stability of the QacR derivatives. The
position of migration of QacR (23 kDa) relative to molecular size
standards is indicated on the left-hand side. The ability of the QacR
mutants to continue to bind IR1 in vivo and hence repress transcrip-
tion from PqacA was assessed by CAT assays with the divergent fusion
of PqacA to a cat reporter gene that is available in the plasmids encod-
ing these proteins (Fig. 1). CAT activity is reported relative to the level
of expression from PqacA in the presence of wild-type QacR, which was
set at 1.
7104 GRKOVIC ET AL. J. BACTERIOL.
 o
n
 M
ay 3, 2012 by FLINDERS UNIVERSITY O
F SO
UTH AUSTRALIA
http://jb.asm.org/
D
ow
nloaded from
 
Purified cysteineless QacR has greatly enhanced in vitro
stability. Examination by SDS-PAGE of purified C72A/C141S
and wild-type QacR proteins after a 4-h incubation at room
temperature indicated that the cysteineless derivative exhib-
ited greatly enhanced in vitro stability compared to the wild-
type protein (Fig. 3). The C72A/C141S QacR protein lacked
the many oligomeric forms that were observed for wild-type
QacR in the absence of reducing agents (Fig. 3).
As described previously (7), the large number of multimeric
forms presumably consisted of different combinations of inter-
and intramolecular disulfide bonds (Fig. 3). These multimers
have also been demonstrated to form, albeit more slowly, in
the presence of reducing agents (7). Importantly, in contrast to
the substantial amounts of wild-type QacR that existed as a
faster-migrating disulfide-bonded monomeric form, even in
the presence of 20 mM 2-mercaptoethanol, the cysteineless
QacR protein preparations completely lacked this species (Fig.
3). However, silver staining did detect very small amounts of
purified cysteineless QacR migrating at a position equivalent
to that expected for a QacR dimer (46 kDa; Fig. 3, first two
lanes), suggesting that QacR exists as dimers in solution, which
can subsequently become covalently linked by degradation
pathways other than the formation of disulfide bonds. This
supported the proposition that the active form of QacR would
most likely be a dimer, as for other TetR family members.
Detection of QacR dimers in solution. Passage of the C72A/
C141S QacR protein through a gel filtration column produced
two peaks, one consistent with a monomeric form of QacR,
while the second, smaller peak eluted close to the void volume
of the column, indicating highly aggregated protein. Attempts
to concentrate QacR beyond 5 mg ml1, even in the presence
of 300 mM NaCl, resulted in the protein precipitating out of
solution. However, by addition of IR1 DNA, the solubility of
purified cysteineless QacR could be markedly increased, sim-
ilar to the prevention of aggregate formation that has been
observed for the BmrR multidrug-binding regulatory protein
(18).
To identify the active oligomeric form of QacR, cross-linking
experiments were carried out with dilute cysteineless QacR
that had first been separated from any aggregated protein by
gel filtration. After treatment with the cross-linking reagent
gluteraldehyde or formaldehyde, separation by SDS-PAGE,
and subsequent immobilization on a nitrocellulose membrane,
monomeric and any covalently joined oligomeric forms of
QacR were detected immunologically using the polyclonal
QacR-specific antibody. Treatment with either reagent re-
sulted in the detection of a covalently linked QacR complex of
a size close to that expected for dimeric QacR, 46 kDa (Fig. 4).
Formation of cross-linked QacR dimers was not significantly
enhanced by the presence of IR1 DNA despite its marked
effect on the solubility of the protein, nor did the addition of
IR1 DNA promote the formation of any other higher-order
oligomeric forms (Fig. 4). The inclusion of compounds that are
inducers of qacA expression in cross-linking reactions also
failed to have an impact on the outcome of these experiments
(data not shown).
Two QacR dimers bind per IR1 operator site. In contrast to
the cross-linking results presented above, gel filtration indi-
cated that four QacR molecules bound each IR1 DNA site. In
three independent gel filtration experiments, using the C72A/
C141S QacR derivative preincubated with molar ratios of be-
tween 0.25 and 0.5 of the purified, complementary, annealed
28-mer IR1 oligonucleotides (Fig. 1), an average molecular
mass of 105.7  3.1 kDa for a QacR-DNA complex was ob-
tained. This value is in good agreement with the theoretical
mass of 109.3 kDa for four QacR molecules bound to the 28-bp
IR1 DNA fragment. The results of a representative gel filtra-
tion experiment are depicted in Fig. 5.
The oligomerization state of QacR was also examined by
DLS measurements in the absence of both DNA and drug
(apo-QacR), the presence of the high-affinity IR1 DNA-bind-
ing site, the presence of a 33-bp noncognate DNA sequence,
and the presence of known inducing compounds. DLS mea-
surements of a 10 M solution of apo-QacR yielded a molec-
ular mass of 43  5 kDa as fit by a bimodal analysis, which
showed 98% of the species with this molecular mass and the
FIG. 3. In vitro stability of purified wild-type and cysteineless
QacR. Following the purification of wild-type (WT) QacR or the
cysteineless (CL) C72A/C141S derivative, the indicated amounts of
purified protein were incubated for 4 h at 22°C before the samples
were heated without () or with () 33 mM DTT. After separation by
SDS–15% PAGE, the proteins were visualized by silver staining. Sam-
ples labeled A were in elution buffer containing 20 mM 2-mercapto-
ethanol, whereas samples labeled B had first been exchanged into a
buffer devoid of reducing agents. Arrows indicate the migration posi-
tions of the two monomeric forms of QacR that were detected and also
the position of the small amounts of a QacR species equivalent in size
to a dimer that was detected in the first two lanes for the cysteineless
derivative. The positions of migration of size standards (in kilodaltons)
are shown on the right-hand side.
TABLE 1. Induction of wild-type and cysteineless QacR derivatives
Inducing
compound
Concn
(g/ml)
Relative CAT activitya
Wild
type
C72A/
C141S
C72A/
C141A
Benzalkonium 10 7.5 7.0 7.0
Dequaliniumb 10 12.9 14.1 16.8
Ethidium 30 1.4 1.5 1.4
Proflavine 10 3.0 4.5 3.4
Rhodamine 6G 100 6.7 6.4 5.3
a The amount of CAT activity detected from PqacA for each of the constructs
in the absence of any inducing compound was set at 1.0. Expression from PqacA
fused to a cat reporter gene with qacR in cis, encoding either wild-type QacR or
a cysteineless derivative, was assayed as described previously (7).
b Bivalent inducing compound.
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remaining 2% as an aggregate with a mass of 980 kDa. The
former molecular mass is consistent with a QacR dimer. In the
presence of the 28-bp IR1 site, the QacR-DNA solution was
completely monodisperse, with no indication of other molec-
ular mass species. The single molecular mass species observed
was 120  3 kDa (the average of three independent experi-
ments in which the individual molecular masses were 120, 124,
and 116 kDa). This molecular mass describes a macromolec-
ular complex in which a tetramer of QacR is bound to a duplex
IR1 site.
Also investigated was the oligomerization state of QacR
following the addition of the QacA monovalent substrate
proflavine or the bivalent substrate dequalinium, compounds
that have been shown to both induce expression of qacA in vivo
and disassociate QacR from operator DNA in vitro (7). Addi-
tion of proflavine at a greater than 20-fold molar excess to the
QacR-IR1 solution, followed by extensive filtering to remove
particulates, reduced the molecular mass to 43  8 kDa, again
using a monomodal analysis. A similar result was observed
when dequalinium was added to a QacR-IR1 solution (data
not shown). The sole presence of the 43-kDa molecular mass
species indicates that two dimers of QacR are induced off the
IR1 operator site. At these concentrations, there was no evi-
dence of monomeric or tetrameric QacR-drug complexes. In
contrast to the QacR-IR1 measurements, when a noncognate
DNA oligonucleotide was included with QacR, a single mo-
lecular mass species of 43  6 kDa was found, which again is
consistent with only a QacR dimer. This confirmed the previ-
ously demonstrated specificity of QacR for the IR1 operator
(7) and furthermore established that formation of DNA-bound
QacR tetramers occurs explicitly in the presence of IR1.
Binding of QacR to DNA requires correctly spaced IR1
half-sites. A mutagenic approach was used to investigate the
significance of the IR1 spacer region to the ability of QacR
dimers to bind operator DNA. Due to the availability of the
previously constructed plasmid pSK5688, in which PqacA had
been repositioned so that the 6 bp normally separating the two
IR1 half-sites had been replaced with the 10 hexamer of this
promoter (Fig. 6), analysis of this alternative PqacA/IR1 ar-
rangement provided an initial indication of the importance of
the 6-bp spacer.
CAT assays demonstrated that, compared to the level of
repression observed for the wild-type promoter (pSK5249; Fig.
6A), the variant PqacA/IR1 (pSK5688; Fig. 6B) exhibited an
almost 10-fold increase in the extent to which its transcription
was repressed (data not shown). In contrast, in the absence of
qacR, the altered PqacA/IR1 sequence directed 0.89-fold the
transcription observed for the equivalent plasmid containing a
wild-type promoter (pSK5203). Although the dramatic en-
hancement of the ability of the variant PqacA in pSK5688 to be
repressed by QacR may well be due to an increased efficiency
in the blocking of RNA polymerase binding, as has been dem-
onstrated for the lac system (12), it could not be ruled out that
the alteration of IR1 had instead produced a sequence which
was bound more efficiently by QacR.
Hence, to more accurately investigate what significance the
FIG. 4. Detection of cross-linked QacR dimers. Purified C72A/
C141S QacR protein, 80 ng (lanes 1 to 4) or 160 ng (lanes 5 and 6), was
preincubated for 15 min with no () DNA (lanes 1, 3, and 5) or with
() 15 ng of 28-bp IR1 DNA (lanes 2 and 4) or 30 ng of 28-bp IR1
DNA (lane 6). Samples in lanes 3 and 4 were cross-linked with 0.01%
gluteraldehyde for 1.5 min and those in lanes 5 and 6 were cross-linked
with 1% formaldehyde for 10 min before the reactions were stopped by
the addition of one-half volume of 2 SDS-PAGE loading buffer,
heated at 95°C for 3 min, and separated by SDS–12.5% PAGE. After
transfer to nitrocellulose, proteins were detected with an anti-QacR
polyclonal antibody. On the left-hand side, the positions of migration
of monomeric and dimeric forms of QacR and molecular size markers
(in kilodaltons) are indicated.
FIG. 5. Gel filtration experiment demonstrating that four QacR
molecules are bound per operator site. The x axis values (Ve/V0) were
calculated by dividing the elution volume (Ve) of each standard or
experimental sample by the void volume of the column (V0). Standards
used were: A, -amylase (Mr 200,000); B, gamma globulin (Mr
158,000); C, ovalbumin (Mr 44,000); D, carbonic anhydrase (Mr
29,000); and E, myoglobin (Mr 17,000). The experimentally deter-
mined values for purified C72A/C141S QacR and the complex it forms
with the 28-bp IR1 DNA fragment are indicated.
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size and/or sequence of the 6-bp spacer region had to QacR
binding, a number of further mutations more closely related to
the wild-type PqacA/IR1 sequence were produced in pSK5249,
and the absolute CAT activities of these fusions were deter-
mined as shown in Fig. 6C. The simultaneous alteration of all
6 bp in pSK5857 led to only a small decrease in the ability of
QacR to repress expression from PqacA in comparison to the
wild-type (pSK5857, 7.16, versus pSK5249, 2.43; Fig. 6C).
However, a CAT activity that was almost comparable to the
level of transcription that occurs in the absence of QacR
(pSK5203, 41.61) resulted from a 2-bp increase in the separa-
tion of the IR1 half-sites (pSK5856, 36.82). This indicated that
QacR effectively failed to bind the altered IR1 sequence in
which the spacing of the half-sites had been increased by 2 bp.
Likewise, the value of 47.66 obtained for pSK5834 was in-
dicative of a total lack of QacR binding to an IR1 sequence in
which the spacing between the two half-sites had been de-
creased by 2 bp (Fig. 6C). In combination with the mutations
that changed all 6 bp, these results indicated that the primary
function of the central region of IR1 is to correctly space the
half-sites. The requirement for two half-sites was verified by
gel mobility shift assays, which used a DNA fragment contain-
ing a single IR1 half-site and the wild-type 6-bp spacer region.
QacR did not alter the mobility of the probe DNA in these
experiments (data not shown).
To further investigate the relatively small reduction in re-
pression observed for the 6-bp mutant (pSK5857; Fig. 6C), two
further mutations that introduced transversions at positions
1 and 1 (pSK5858) or 3 and 2 (pSK5859) were con-
structed. Surprisingly, transversions at the central 2 bp
(pSK5858; Fig. 6C) produced an operator that was bound less
efficiently than the one in which all 6 bp had been mutated
(pSK5857; Fig. 6C), perhaps because the latter construct con-
tained only a transversion at the 1 position, with a transition
at 1. In addition to bp 1 and 1 contributing to the overall
twofold symmetry of the IR1 sequence (Fig. 6A), their pres-
ence in an organism with a very low GC content further rein-
forces the finding that the actual sequence of the central 2 bp
appears to be more important than that of the surrounding 4
bp. The increased repression of the mutant operator contain-
ing transversions at the 3 and 2 positions (pSK5859; Fig.
6C) was also a somewhat unexpected result. Interestingly, the
initial “10” mutation in pSK5688, which was strongly re-
pressed by QacR, also possessed the same transversions at
positions 3 and 2 as the pSK5859 operator, in addition to
introducing transitions, and not transversions, at the central 2
bp (Fig. 6).
DISCUSSION
A number of proteins, including human fibroblast growth
factor 1 (5), T4 lysozyme (23), and Bacillus -amylases (33),
have, like QacR, been observed to form disulfide-bonded mul-
timeric degradation products following purification. Of partic-
ular concern, in the case of QacR, was the large amount of the
monomeric species containing an intramolecular disulfide
bond (Fig. 3), which appeared to form either during or imme-
diately upon purification. Circumvention of this problem re-
quired the removal of the two cysteine residues, which resulted
in the production of an engineered, fully functional, cysteine-
less QacR (C72A/C141S) derivative with greatly enhanced in
vitro stability.
The cysteine residues of some regulatory proteins have been
found to be essential, e.g., forming part of the DNA-binding
domain in zinc finger proteins (21) or playing a fundamental
role in the binding of cationic metal ligands by other regulatory
proteins, such as MerR (34) and ArsR (28). Retention of full
DNA-binding capabilities by the cysteineless derivative was
validated both in vivo (Fig. 2) and in vitro, demonstrating that
the C72 and C141 residues were not required for the binding of
QacR to IR1 DNA. Likewise, the ability of cysteineless QacR
to continue to mediate wild-type levels of induction from PqacA
in vivo (Table 1) indicated that the two cysteine residues do not
play an important role in drug binding or the communication
of the ligand-binding state to the DNA-reading head.
The gel filtration data (Fig. 5), taken together with the cross-
linking (Fig. 4) and DLS results, show that two separate QacR
dimers bind to IR1 DNA either independently or, alterna-
tively, with only limited dimer-dimer interactions. A revised
model for the regulation of qacA expression by QacR is there-
fore proposed, in which induction results in the dissociation of
FIG. 6. Relevant portion of the wild-type PqacA/IR1 sequence car-
ried by pSK5249 and pSK5203 (A) and the alternative PqacA/IR1 ar-
rangement in pSK5688, in which the 10 and 35 hexamers (under-
lined) of the qacA promoter have been repositioned so that the 10
region is located between the two half-sites of IR1 (B). (C) The
sequence of the central region separating the two IR1 half-sites is
given for plasmids that contain either the wild-type 6 bp (pSK5203 and
pSK5249), substitutions to all 6 bp (pSK5857), a 2-bp increase
(pSK5856) or decrease (pSK5834) in the spacing between the two
half-sites, transversions in the 1 and 1 positions (pSK5858), or
transversions in the 3 and 2 positions (pSK5859). A line delineates
the center of the twofold symmetry between the IR1 half-sites. The
bases are numbered as for Fig. 1, with non-wild-type IR1 nucleotides
indicated in bold. The absolute CAT activities for fusions of these
various PqacA/IR1 sequences to a cat reporter gene (expressed as mi-
cromoles of chloramphenicol acetylated per minute per milligram of
protein) were determined for plasmids with qacR in cis, with the
exception of pSK5203, which lacked the qacR gene.
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the two dimers bound to an IR1 site, to form two separate
ligand-bound dimers. DLS experiments provided proof of this
event, demonstrating that the four molecules of QacR bound
to operator DNA again assumed dimeric forms in the presence
of inducing compounds. This result also strongly supported the
postulate that QacR does not self-assemble into a tetrameric
form, as did the failure of the cross-linking experiments to
produce any covalently linked complexes larger in size than a
dimeric form of QacR. As both formaldehyde and gluteralde-
hyde are generally considered to be zero-length cross-linking
agents, the two QacR dimers bound to each IR1 site are
therefore likely to have no or only very limited direct dimer-
dimer interactions, such that no side-chains are available for
cross-linking by these reagents. Formaldehyde and gluteralde-
hyde also did not produce any covalently linked QacR-DNA
complexes that contained four protein molecules, which is con-
sistent with the failure to obtain cross-linked protein-operator
complexes for other sequence-specific DNA-binding regula-
tory proteins (29). The apparent anomaly of apo-QacR eluting
from the Superose gel filtration column as a monomer is likely
to reflect the ability of this matrix on rare occasions to tempo-
rarily monomerize native dimers, a situation previously ob-
served for the Toxoplasma gondii uracil phosphoribosyltrans-
ferase (M. A. Schumacher and R. G. Brennan, unpublished
data).
Despite all the evidence obtained in this study indicating
that QacR does not self-assemble into a tetrameric form prior
to DNA binding, no intermediate forms equivalent to one
QacR dimer bound per IR1 site were detected in gel mobility
shift assays, even at protein concentrations that did not bind all
the available operator DNA (7). This result is not surprising,
considering that both in vivo (7) and in vitro QacR failed to
bind to DNA that contained only a single IR1 half-site. Some
form of distance-dependent cooperativity in the binding of a
pair of dimers to IR1 was clearly supported by the almost
complete inability of QacR to bind operator sequences in
which the spacing of the IR1 half-sites had been increased or
decreased by 2 bp (Fig. 6C), particularly in light of the contin-
ued ability of QacR to bind operator sequences which con-
tained substitutions to all of the central 6 bp.
A mechanism for cooperative binding of QacR dimers to
IR1 that involved indirect interactions through the DNA
would be consistent with all the results presented in this work.
Such a scenario is not unwarranted, as monomers of the hu-
man regulatory protein RFX1 have been shown to bind DNA
cooperatively, forming dimers that have no direct protein-pro-
tein interactions; instead, the cooperativity appears to occur
via protein-induced deformation of the binding site (4, 6).
Thus, the actual sequence of the central 6 bp of IR1 may make
a contribution to the cooperative binding of QacR dimers via
influencing the local structure of the operator DNA, in addi-
tion to their primary role of correctly spacing the half-sites.
Alternatively, data from the DNase I footprint (Fig. 1), to-
gether with that from the mutations in the central 6 bp (Fig.
6C), could be taken to indicate that QacR makes some direct
DNA contacts to the central spacer that are for the most part
sequence nonspecific.
Of interest was the finding that a simple 2-bp mutation
introduced at positions 3 and 2 of IR1 produced an oper-
ator that exhibited significantly improved repression (pSK5859;
Fig. 6C). This observation provides some corroboration for an
earlier proposal that the natural QacR/IR1 system is designed
to provide a significant basal level of qacA expression in order
to protect the cell against compounds that are substrates of the
QacA multidrug pump but not ligands of the QacR transcrip-
tional repressor (7).
The demonstration that two QacR dimers bind to IR1 was
unexpected, considering that the other TetR family members
for which the DNA-binding stoichiometry is known, bind as
one dimer per operator, e.g., TetR (9) and CamR (3). How-
ever, in contrast to the above proteins, QacR binds to an
exceptionally large, 36-bp inverted repeat (Fig. 1). The DNase
I footprint (7), in combination with the spacer region muta-
tions (Fig. 6), suggests that QacR interacts directly with a
region of DNA consisting of 20 to 28 bp, or at least 10 bp per
half-site, which is in stark contrast to the 6-bp DNA-binding
capacity of a typical helix-turn-helix (HTH) motif (8, 31).
Therefore, in order to bind a single IR1 half-site, the DNA-
reading heads of both molecules in one QacR dimer appear to
be required, which would account for the observed QacR
DNA-binding stoichiometry (Fig. 5). Although the DNA “rec-
ognition” helix of TetR compensates for its abnormally short
length by making an exceptionally large number of contacts
with tet operator DNA (20), QacR may have acquired an
alternative solution to ensure that an adequate number of
DNA contacts are made by employing a dimer to bind to each
operator half-site.
Although MetJ family regulatory proteins also employ one
dimer to bind each of their operator half-sites, unlike QacR,
these proteins have been shown to form tetramers that involve
substantial dimer-dimer interactions, in addition to binding
DNA with an antiparallel -sheet motif and not an HTH (30).
The lack of any apparent internal symmetry within an IR1
half-site (Fig. 1) suggests that the contacts a QacR dimer
makes to DNA may be largely nonsymmetrical, as has been
found for a MetJ family member, the bacteriophage P22 re-
pressor Arc (24). Further prokaryotic regulatory proteins that
bind DNA as higher-order oligomers have been shown to self-
assemble from dimers into tetramers, as in the case of LacR
(14), and from dimers into octamers, in the case of the lambda
repressor (27). In both of the above examples, the dimeric
units making up the higher-order oligomers are used to bind
distinct operators.
Analysis of the region of DNA encoding the qacA and qacR
genes failed to detect any additional sequences exhibiting sim-
ilarity to IR1, and it has been established that QacR does not
interact with the dissimilar IR2 inverted repeat located in the
vicinity of the qacR promoter (7). This further supports a
model in which separate QacR dimers are used to bind the two
IR1 operator half-sites by a cooperative process that does not
require the prior self-assembly of QacR into tetramers.
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